Literature DB >> 8498410

Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use.

K J Moise1.   

Abstract

OBJECTIVE: The objective of this study was to determine whether indomethacin is associated with an increased incidence of constriction of the human fetal ductus arteriosus with advancing gestational age. STUDY
DESIGN: A retrospective analysis of fetal echocardiograms performed in 44 patients with premature labor or hydramnios treated with indomethacin (25 mg orally every 6 hours) was undertaken. Fisher's exact test, Kaplan-Meier survival analysis, and log-rank techniques were used; a value of p < 0.05 was considered statistically significant.
RESULTS: The frequency of ductal constriction was similar for fetuses of singleton and multiple gestations. A dramatic increase in constriction was noted at 32 weeks' gestation when the rate of compromise approached 50%.
CONCLUSIONS: The use of indomethacin should be restricted to gestational ages of < 32 weeks. In multiple gestations each fetus should be evaluated by echocardiography, because the ductal response may vary between individual fetuses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8498410     DOI: 10.1016/s0002-9378(11)90763-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  20 in total

1.  Metaanalysis of the effect of antenatal indomethacin on neonatal outcomes.

Authors:  Sanjiv B Amin; Robert A Sinkin; J Christopher Glantz
Journal:  Am J Obstet Gynecol       Date:  2007-11       Impact factor: 8.661

Review 2.  Fortnightly review: drug treatment during pregnancy.

Authors:  P Rubin
Journal:  BMJ       Date:  1998-11-28

3.  Inhibition of cyclooxygenase isoforms in late- but not midgestation decreases contractility of the ductus arteriosus and prevents postnatal closure in mice.

Authors:  Jeff Reese; Judy D Anderson; Naoko Brown; Christine Roman; Ronald I Clyman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-07-20       Impact factor: 3.619

Review 4.  NSAID-induced nephrotoxicity from the fetus to the child.

Authors:  L Cuzzolin; M Dal Cerè; V Fanos
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.606

5.  Coordinated regulation of fetal and maternal prostaglandins directs successful birth and postnatal adaptation in the mouse.

Authors:  J Reese; B C Paria; N Brown; X Zhao; J D Morrow; S K Dey
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

Review 6.  Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period.

Authors:  Jeff Reese; Alex Veldman; Lisa Shah; Megan Vucovich; Robert B Cotton
Journal:  Semin Perinatol       Date:  2010-06       Impact factor: 3.300

7.  Reversible ductus arteriosus constriction due to maternal indomethacin after fetal intervention for hypoplastic left heart syndrome with intact/restrictive atrial septum.

Authors:  Melanie Vogel; Louise E Wilkins-Haug; Doff B McElhinney; Audrey C Marshall; Carol B Benson; Virginia Silva; Wayne Tworetzky
Journal:  Fetal Diagn Ther       Date:  2009-12-17       Impact factor: 2.587

8.  Spontaneous Rhythmic Contractions (Vasomotion) of the Isolated, Pressurized Ductus Arteriosus of Preterm, but Not Term, Fetal Mice.

Authors:  Megan Vucovich; Noah Ehinger; Stanley D Poole; Fred S Lamb; Jeff Reese
Journal:  EJ Neonatol Res       Date:  2012-01

9.  Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies.

Authors:  Afif El-Khuffash; Amish Jain; David Corcoran; Prakesh S Shah; Christopher W Hooper; Naoko Brown; Stanley D Poole; Elaine L Shelton; Ginger L Milne; Jeff Reese; Patrick J McNamara
Journal:  Pediatr Res       Date:  2014-06-18       Impact factor: 3.756

10.  Cyclooxygenase-1-selective inhibition prolongs gestation in mice without adverse effects on the ductus arteriosus.

Authors:  Charles D Loftin; Darshini B Trivedi; Robert Langenbach
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.